Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Immunity And The Suppression Equipment Supplied In Usa
37 equipment items found
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
Expressing reprogramming proteins by repeated transfection with protein-encoding RNA could avoid the limitations of both DNA and protein-based reprogramming techniques. However, transfection with long, in vitro-transcribed RNA triggers a potent innate immune response in human cells, even when the RNA is capped and polyadenylated to mimic eukaryotic mRNA. To address this problem, ...
by:Saneron CCEL Therapeutics, Inc. based inTampa, FLORIDA (USA)
The SERT-CELL program explores the unique potential of Sertoli cells, protein-rich cells found in the mammalian testes, which inhibit immune reactions to foreign tissues, including transplants. Sertoli cells provide localized immunosuppression, which mitigates the need for a patient to undergo costly and potentially dangerous immune suppression, ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for PAD4 inhibitors in autoimmune ...
Manufactured by:DxTerity Diagnostics Inc. based inRancho Dominguez, CALIFORNIA (USA)
The DxTerity Immunity Assessment Test measures COVID-19 neutralizing antibody levels from a small sample of blood. Knowing your neutralizing antibody levels can help you assess your risk of future symptomatic ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-106, an antagonist antibody targeting LAIR1, an immune inhibitory receptor. The company’s preclinical research supports the proposed mechanisms of action of IO-106 and its evaluation as a potential treatment for solid ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
by:Cyrus Biotechnology Inc. based inSeattle, WASHINGTON (USA)
Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator.44 This activation is thought to starve cancer cells of important molecular building blocks, inhibiting tumor cell proliferation, and enhancing antitumor ...
Manufactured by:Cabaletta Bio, Inc. based inPhiladelphia, PENNSYLVANIA (USA)
DSG3/1-CAART is being developed to treat mucocutaneous pemphigus vulgaris (mcPV), a B cell-mediated autoimmune disease that causes blistering of the skin and mucous membranes. mcPV is caused by autoantibodies that attack the cell adhesion proteins DSG3 and DSG1. DSG3/1-CAART is designed to selectively target and kill the B cells that express the pathogenic autoantibodies while preserving the ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
Current evidence suggests that a pro-inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES009 is a potential best-in-class monoclonal antibody targeting LILRB2 designed to reprogram inhibitory myeloid cells to create an immune favorable TME. LILRB2 is an inhibitory receptor that suppresses myeloid cell activation. Blocking LILRB2 reverses immunosuppression by reprograming tumor-associated macrophages (TAMs) from M2 (pro-tumor) to M1 (anti-tumor) ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME). Solid tumors frequently express TGF-β, which suppresses T cell activation and induces CD39 expression, the rate-limiting enzyme in the ATP-adenosine pathway. ...
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
Why human derived? Brooklyn has developed a powerful method to create complex cytokine mixtures derived from a human source. Cytokines are powerful immune factors that play an essential role in T cell signaling, activation, proliferation, and tumor-fighting responses. We know cytokines may induce beneficial reactions in cancer patients. To date, available cytokine therapies have been recombinant ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also plays an important role in creating an immune suppressive TME. Pre-clinical and early clinical data of ES104 show that blocking both ...
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
IRX-2 is a human-derived mixed cytokine product containing more than 29 cytokines that promote or enhance a complex immune response. Scientists are developing IRX-2 as a cancer immunotherapy. IRX-2 is administered as a subcutaneous injection around lymph node beds near the tumor target. IRX-2 is produced under cGMP (current good manufacturing process) conditions following stimulation of a ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Our approach to autoimmune disease is designed to restore natural self-tolerance by administering ImmTOR with nanoparticles-encapsulated self-antigens and avoid the need for chronic and systemic immune suppression. ...
by:BioAesthetics Corporation based inResearch Triangle Park, NORTH CAROLINA (USA)
BioAesthetics’ Nipple-Areolar Complex Graft, or NACgraft, is a revolutionary next step in breast reconstruction that will provide patients who have had mastectomies with a new, natural, living nipple and areola. We created NACgraft because we believe breast cancer survivors deserve an effective nipple reconstruction process that looks and feels great. The NACgraft is a cell-free, ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the immune responses to tumor cells. The Treg is a type of T cell that is important in preventing autoimmunity by keeping effector T cells [Teffs] “in-check” to prevent destruction of healthy tissues. However, around tumors, Tregs ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia ...